RecruitingPhase 2NCT05130177

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase II Study of PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Sponsor

Diwakar Davar

Enrollment

26 participants

Start Date

Mar 16, 2022

Study Type

INTERVENTIONAL

Conditions

Melanoma

Summary

The main goal of this study is to establish the proportion of patients with objective response to zimberelimab/domvanalimab in PD-1 R/R melanoma patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a combination of two immunotherapy drugs — zimberelimab and domvanalimab — for people with melanoma (skin cancer) whose cancer stopped responding to standard immunotherapy (PD-1 inhibitors). **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with cutaneous melanoma (skin melanoma) or melanoma of unknown origin - Your melanoma has relapsed or stopped responding to prior PD-1 immunotherapy - You are not pregnant or breastfeeding - You agree to use contraception during and after treatment **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your melanoma has not been previously treated with PD-1 therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZimberelimab

Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.

DRUGDomvanalimab

Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.